3 chapters across the catalog
Novartis Swine Flu Vaccine Adjuvants and FDA Evaluation
The FDA is evaluating a new swine flu vaccine from Novartis that utilizes the adjuvant MF59. This development follows predictions that pharmaceutical companies would push for adjuvanted vaccines to stretch the supply of viral antigens and speed up the inoculation process.
Novartis MF59 Adjuvant, FDA Approval and Liability Immunity
Pharmaceutical companies like Novartis are using experimental adjuvants such as MF59 in swine flu vaccines, despite a lack of long-term data on how they function. Health and Human Services Secretary Kathleen Sebelius signed a decree granting vaccine makers total immunity from liability for injuries caused by these shots. Critics argue the pandemic is being used as a loophole to conduct mass human testing of unapproved vaccine additives.
Squalene Adjuvants, Military Testing and Fort Detrick
The use of squalene in vaccine adjuvants has a controversial history linked to military testing and Gulf War Syndrome. Research into these emulsion vehicles began at Fort Detrick in 1987, and the military has a history of administering experimental shots to service members without detailed record-keeping. These same compounds are now being integrated into public swine flu vaccines under various commercial names.
